Please login to the form below

Not currently logged in
Email:
Password:

Cristal Therapeutics names chief medical officer

Edwin Klumper joins from contract research firm SMS-oncology 

Cristal Therapeutics, a privately-held life sciences company based in The Netherlands, has appointed Edwin Klumper as its chief medical officer.

In his new role, Klumper will be responsible for the clinical strategy and development of Cristal Therapeutics' range of nanomedicines.

He joins the pharmaceutical firm from SMS-oncology, a CRO specialising in clinical development studies in oncology, which he co-founded in 2007.

Klumper served as its chief medical officer until 2013 when he became the organisation's interim chief executive.

Prior to this, Klumper served as vice president, marketing and sales Europe at Nabi Biopharmaceuticals and business unit director for The Netherlands at Amgen.

He also brings experience from ASTA Medica and start-up Yew Tree Pharmaceuticals where he served as its medical director.

Joost Holthuis, Cristal Therapeutics' chief executive officer, said: “We are extremely fortunate to have Edwin joining our leadership team.

“Edwin will no doubt contribute to the already firm nanomedicine programme of CriPec docetaxel, as well as help up move forward in our efforts to develop novel proprietary nanomedicines.”

4th May 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
Guide
How to embrace behavioural science principles in healthcare MR...